title: Bertilimumab Cambridge Antibody Technology Group.
abstract: Cambridge Antibody Technology (CAT) is developing bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.
authors.affiliation: Menzies Research Institute, University of Tasmania, Hobart 7000, Tasmania, Australia. changhai.ding@utas.edu.au
authors.forename: Changhai
authors.initials: C
authors.lastname: Ding
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Xuejue
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000037:antagonists & inhibitors*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy; D054397:Receptors, CCR3; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
chemical_list: D000911:Antibodies, Monoclonal; C515456:CCL11 protein, human; C515350:CCR3 protein, human; D054413:Chemokine CCL11; D019742:Chemokines, CC; D054397:Receptors, CCR3; D019707:Receptors, Chemokine